CORE is a phase 3 multicenter, randomized, double-blind, placebo-controlled trial of ~540 patients to evaluate the safety and efficacy of ISIS 678354, an antisense oligonucleotide inhibitor of apoC-III production, administered subcutaneously to patients with severe hypertriglyceridemia.
MAIN RESULTS:
Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk
N Engl J Med. 2025 Nov 8. doi: 10.1056/NEJMoa2512761. Online ahead of print.
PRESENTATIONS
PUBLICATIONS
CORE on ClinicalTrials.gov
Contact Us about CORE